Muscular dystrophies due to glycosylation defects
In the last few years, muscular dystrophies due to reduced glycosylation of alpha-dystroglycan (ADG) have emerged as a common group of conditions, now referred to as dystroglycanopathies. Mutations in six genes (POMT1, POMT2, POMGnT1, Fukutin, FKRP and LARGE) have so far been identified in patients with a dystroglycanopathy. Allelic mutations in each of these genes can result in a wide spectrum of clinical conditions, ranging from severe congenital onset with associated structural brain malformations (Walker Warburg syndrome; muscle-eye-brain disease; Fukuyama muscular dystrophy; congenital muscular dystrophy type 1D) to a relatively milder congenital variant with no brain involvement (congenital muscular dystrophy type 1C), and to limb-girdle muscular dystrophy (LGMD) type 2 variants with onset in childhood or adult life (LGMD2I, LGMD2L, and LGMD2N).
ADG is a peripheral membrane protein that undergoes multiple and complex glycosylation steps to regulate its ability to effectively interact with extracellular matrix proteins, such as laminin, agrin, and perlecan.
Although the precise composition of the glycans present on ADG are not known, it has been demonstrated that the forced overexpression of LARGE, or its paralog LARGE2, is capable of increasing the glycosylation of ADG in normal cells. In addition, its overexpression is capable of restoring dystroglycan glycosylation and laminin binding properties in primary cell cultures of patients affected by different genetically defined dystroglycanopathy variants.
These observations suggest that there could be a role for therapeutic strategies to overcome the glycosylation defect in these conditions via the overexpression of LARGE.
Endo T. O-mannosyl glycans in mammals. Biochim Biophys Acta 1999;1473: 237–246.PubMed
Endo T, Manya H. O-mannosylation in mammalian cells. Methods Mol Biol 2006;347: 43–56.PubMed
Henry MD, Satz JS, Brakebusch C, et al. Distinct roles for dystroglycan, betal integrin and perlecan in cell surface laminin organization. J Cell Sci 2001;114: 1137–1144.PubMed
Brown SC, Fassati A, Popplewell L, et al. Dystrophic phenotype induced in vitro by antibody blockade of muscle alpha-dystrogly-can-laminin interaction. J Cell Sci 1999;112(Pt 2): 209–216.PubMed
Sabatelli P, Columbaro M, Mura I, et al. Extracellular matrix and nuclear abnormalities in skeletal muscle of a patient with Walker-Warburg syndrome caused by POMT1 mutation. Biochim Biophys Acta 2003;1638: 57–62.PubMed
Matsumoto H, Noguchi S, Sugie K, et al. Subcellular localization of fukutin and fukutin-related protein in muscle cells. J Biochem (Tokyo) 2004;135: 709–712.
Hirst RC, McCullagh KJ, Davies KE. Utrophin upregulation in Duchenne muscular dystrophy. Acta Myol 2005;24: 209–216.PubMed
- Muscular dystrophies due to glycosylation defects
Volume 5, Issue 4 , pp 627-632
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Alpha dystroglycan
- laminin binding
- pharmacological upregulation
- Industry Sectors